Apellis Pharmaceuticals, Inc.
APLSDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001492422
Apellis Pharmaceuticals, Inc. was delisted in 2026; its insiders filed their last Form 4 on May 14, 2026; 324 institutions reported holding it in 13F filings for Q1 2026, worth $5.56B in total; Soros Fund Management was the only superinvestor holding it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 324
- Q1 2026, +49 vs. previous quarter
- 13F value
- $5.56B
- Reported value at the end of Q1 2026
- Superinvestors holding
- 1
- At the end of Q1 2026
Superinvestors holding APLS, Q1 2026
1 superinvestor reports holding Apellis Pharmaceuticals, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Soros Fund Management
George Soros
0.6%
Apellis Pharmaceuticals, Inc.'s share of the portfolio
- Shares
- 1,056,000
- Value
- $42.5M
Latest insider trades
Open-market purchases and sales by Apellis Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 13, 2026 (view filing) | Feb 11 | 2 days | DeLong Mark JeffreyChief Business & Strat Officer | SSale | −368 | $22.15 | −$8.15K | −0.3%114.6K after | |
| Jan 23, 2026 (view filing) | Jan 22 | 1 day | Baumal CarolineChief Medical Officer | SSale | −2.80K | $21.77 | −$60.9K | −3.1%86.5K after | |
| Jan 23, 2026 (view filing) | Jan 22 | 1 day | Chopas James GeorgeVP/Chief Accounting Officer | SSale | −2.06K | $21.77 | −$44.9K | −4.0%49.8K after | |
| Jan 23, 2026 (view filing) | Jan 22 | 1 day | DeLong Mark JeffreyChief Business & Strat Officer | SSale | −3.37K | $21.77 | −$73.4K | −4.1%78.4K after | |
| Jan 23, 2026 (view filing) | Jan 22 | 1 day | Deschatelets PascalChief Scientific Officer | SSale | −5.93K | $21.77 | −$129.1K | −0.5%1.15M after | |
| Jan 23, 2026 (view filing) | Jan 22 | 1 day | Francois CedricChief Executive Officer | SSale | −27.2K | $21.77 | −$592.0K | −8.7%286.0K after | |
| Jan 23, 2026 (view filing) | Jan 22 | 1 day | Nicholson NurChief Technical Officer | SSale | −7.72K | $21.77 | −$168.2K | −9.8%71.1K after | |
| Jan 23, 2026 (view filing) | Jan 22 | 1 day | Sullivan Timothy EugeneChief Financial Officer | SSale | −10.3K | $21.77 | −$223.9K | −9.9%93.9K after | |
| Jan 23, 2026 (view filing) | Jan 22 | 1 day | Watson David O.General Counsel | SSale | −7.83K | $21.77 | −$170.5K | −8.1%88.5K after | |
| Jan 21, 2026 (view filing) | Jan 20 | 1 day | Baumal CarolineChief Medical Officer | SSale | −1.88K | $19.79 | −$37.2K | −2.1%89.3K after |
Top 10 13F holders, Q1 2026
The largest institutional positions in Apellis Pharmaceuticals, Inc. at the end of Q1 2026; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 13,536,964 | $544.6M | 0.01% | +7,276,851+116.2% | Added |
| Avoro Capital Advisors LLC | 12,222,222 | $491.7M | 4.84% | 00.0% | Unchanged |
| Morgan Stanley | 10,042,399 | $404.0M | 0.02% | +869,395+9.5% | Added |
| State Street Corp | 6,844,990 | $275.4M | 0.01% | +2,231,544+48.4% | Added |
| UBS Group AG | 6,206,681 | $249.7M | 0.04% | +2,020,459+48.3% | Added |
| Vanguard Portfolio Management LLC | 5,404,559 | $217.4M | 0.01% | +5,404,559 | New |
| Pentwater Capital Management LP | 5,250,000 | $211.2M | 1.50% | +5,250,000 | New |
| Vanguard Capital Management LLC | 4,768,944 | $191.9M | 0.00% | +4,768,944 | New |
| Deep Track Capital, LP | 4,532,374 | $182.3M | 3.76% | −3,217,626−41.5% | Reduced |
| Point72 Asset Management, L.P. | 4,183,918 | $168.3M | 0.29% | +3,586,246+600.0% | Added |